Last reviewed 2026-04-23 · How we verify

BIIB091

BIIB091 is a monoclonal antibody targeting CD47.

BIIB091 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.

At a glance

Mechanism of action

CD47 is a protein that can interfere with the body's ability to recognize and destroy cancer cells. By targeting CD47, BIIB091 aims to enhance the body's immune response against cancer.

Approved indications

• Relapsed or refractory multiple myeloma

Common side effects

• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (PHASE2)
• A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants (PHASE1)
• A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants (PHASE1)
• A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (PHASE1)
• Study of BIIB091 Formulations in Healthy Participants (PHASE1)
• A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BIIB091 CI brief — competitive landscape report
• BIIB091 updates RSS · CI watch RSS
• Biogen portfolio CI